Veridex, Lcc

Celgene Corporation

Janssen Diagnostics, LLC

Yixin Wang

Yi Zhang

Tatiana Vener

John W Backus

Fei Yang

Alberto Risueno Perez

Carlo C Derecho

Mitch Raponi

Haiying Wang

Timothy Jatkoe

Hongtao Fan

Dmitri Talantov

Sarah Hersey

Fadi George Towfic

Jonathan Baden

Dong-Ho Lee

Tim Jatkoe

Dongho Lee

Dimitri Talantov

Dondapati Chowdary

Abhijit Mazumder

Jack X Yu

A method of predicting if a subject has an Activated B Cell-like (ABC) subtype or a non-ABC subtype of Diffuse Large B-Cell Lymphoma (DLBCL), comprising (a) obtaining a sample from the subject; (b) measuring the expression levels of CD10, MUM1, FOXP1, and optionally Bcl-6; (c) determining a composite score based on the expression levels of CD10, MUM1, and FOXP1, and optionally Bcl-6; and (d) predicting if the subject has an ABC subtype or a non-ABC subtype of DLBCL based on the composite score.

Methods of classifying diffuse large B-cell lymphoma

A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

Breast cancer prognostics

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA&#xae;), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase

A method of prognosticating metastasis in a breast cancer patient involves identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes as well as kits for employing the method.

Breast cancer prognostic portfolio

A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes. Gene expression portfolios and kits for employing the method are further aspects of the invention.

Cancer diagnostic panel

A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.

Growing community of inventors

San Diego, CA, United States of America

Yixin Wang